Alvotech (ALVO) Acquisitions: History & Chart

Alvotech(ALVO)

Drug Manufacturers - Specialty & Generic · Luxembourg, LU

$6.08-0.03 (-0.49%)

Delayed quote: Oct 6, 2026, 11:34 AM EDT

About Alvotech

Alvotech, along with its various subsidiaries, is dedicated to the global development and manufacturing of biosimilar pharmaceuticals. Its product offerings span key therapeutic categories, encompassing autoimmune conditions, eye disorders, bone diseases, and cancer. A flagship program for the company is AVT02, a high-concentration biosimilar equivalent to Humira. This candidate is designed to address a range of inflammatory illnesses, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis. Similarly, AVT04 is a biosimilar version of Stelara, targeting inflammatory conditions such as psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis. For ophthalmic conditions, AVT06 serves as a biosimilar to Eylea, intended for the treatment of age-related macular degeneration, macular edema, and diabetic retinopathy. Currently in preclinical stages, AVT03 is a biosimilar to Xgeva and Prolia, with the goal of preventing bone fractures, alleviating spinal cord compression, reducing the necessity for radiation or bone surgery in certain cancer patients, and both preventing bone loss and increasing bone density. Additionally, Alvotech's pipeline features AVT05, an early-stage biosimilar for Simponi and Simponi Aria, which is being developed for various inflammatory conditions like rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Other promising candidates include AVT16, an immunology biosimilar; AVT23, a late-stage biosimilar to Xolair, aimed at treating nasal polyps; and AVT33, an oncology biosimilar. Established in 2013, Alvotech maintains its primary corporate headquarters in Reykjavik, Iceland.

Luxembourg, LU

1,279 employees

www.alvotech.com

Healthcare / Drug Manufacturers - Specialty & Generic

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
CEO: Lisa Graver

View full financials

Period	Acquisitions	QoQ Growth	YoY Growth
Q2 FY2026Period end 2026-06-30	$0	N/A	N/A
Q1 FY2026Period end 2026-03-31	$0	N/A	-100.00%
Q4 FY2025Period end 2025-12-31	−$2.98M	+78.80%	N/A
Q3 FY2025Period end 2025-09-30	−$14.04M	N/A	N/A
Q2 FY2025Period end 2025-06-30	$0	-100.00%	N/A
Q1 FY2025Period end 2025-03-31	$2.98M	N/A	N/A
Q4 FY2024Period end 2024-12-31	$0	N/A	N/A
Q3 FY2024Period end 2024-09-30	$0	N/A	N/A
Q2 FY2024Period end 2024-06-30	$0	N/A	N/A
Q1 FY2024Period end 2024-03-31	$0	N/A	N/A
Q4 FY2023Period end 2023-12-31	$0	N/A	N/A
Q3 FY2023Period end 2023-08-31	$0	N/A	N/A
Q2 FY2023Period end 2023-06-30	$0	N/A	N/A
Q1 FY2023Period end 2023-03-31	$0	N/A	N/A
Q4 FY2022Period end 2022-12-31	$0	N/A	N/A
Q3 FY2022Period end 2022-09-30	$0	N/A	N/A
Q2 FY2022Period end 2022-06-30	$0	N/A	N/A
Q1 FY2022Period end 2022-03-31	$0	N/A	N/A
Q4 FY2021Period end 2021-12-31	$0	N/A	N/A
Q3 FY2021Period end 2021-09-30	$0	N/A	N/A
Q2 FY2021Period end 2021-06-30	$0	N/A	N/A
Q1 FY2021Period end 2021-03-31	$0	N/A	N/A
Q4 FY2020Period end 2020-12-31	$0	N/A	N/A
Q3 FY2020Period end 2020-09-30	$0	N/A	N/A
Q2 FY2020Period end 2020-06-30	$0	N/A	N/A
Q1 FY2020Period end 2020-03-31	$0	N/A	N/A
Q4 FY2019Period end 2019-12-31	$0	N/A	N/A
Q3 FY2019Period end 2019-09-30	$0	N/A	N/A
Q2 FY2019Period end 2019-06-30	$0	N/A	N/A
Q1 FY2019Period end 2019-03-31	$0	N/A	N/A

Acquisitions

ALVO Acquisitions

Current Acquisitions

QoQ Growth

Historical Data

Quarterly Acquisitions History

Related Metrics